.....The reason CSL112 isn't listed as 40/50% like the typical cardiovascular drug is due to the lacklustre Phase 2 results and the Pfizer Phase 3 results of a similar drug:....
Yeah, that's what he says in the report, however CSL is wall-to-wall PhDs, and this Goldman Sachs guy is a medical student intern. I mean.......seriously...?
No disrespect intended, but I know who I'm listening to.
.....The reason CSL112 isn't listed as 40/50% like the typical...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$307.80 |
Change
2.460(0.81%) |
Mkt cap ! $148.7B | |||
| Open | High | Low | Value | Volume |
| $305.41 | $308.69 | $304.34 | $158.2M | 514.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13 | $307.77 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $307.80 | 4197 | 1 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| CSL (ASX) Chart |